Publications UniUD

URI permanente per questa collezione

https://ricerca.unityfvg.it/handle/123456789/239333

Sfogliare

Immissioni recenti

Ora in mostra 1 - 5 di 85780
  • Pubblicazione
    PROSPECTIVE RANDOMIZED STUDY COMPARING TRANSPERITONEAL AND EXTRAPERITONEAL APPROACH DURING ROBOTIC PROSTATECTOMY: ANESTHESIOLOGIC EFFECTS
    ( 2013)
    Dal Moro F
    ;
    Valotto C
    ;
    Mangano A
    ;
    Soncin R
    ;
    Crestani A
    ;
    Guttilla A
    ;
    Pittoni GM
    ;
    Zattoni F
  • Pubblicazione
  • Pubblicazione
    Tolicizumab: a new option for refractory idiopathic recurrent pericarditis: a case report
    ( 2025)
    Collini V.
    ;
    Venturelli F.
    ;
    Quinzani F.
    ;
    Sappa R.
    ;
    Imazio M.
    Background Recurrent pericarditis is the most common and troublesome complication of pericarditis and can be particularly challenging when it becomes refractory to conventional therapies, often resulting in a prolonged disease course. Interleukin-1 (IL-1) inhibitors have transformed the management of such cases; however, not all patients tolerate or respond adequately to these agents. Case summary We present a 37-year-old man suffering from idiopathic recurrent pericarditis since the age of 25. After failure of standard therapies, he became corticosteroid-dependent, so treatment with anakinra (an IL-1 inhibitor) was attempted twice, but discontinued early due to allergic reactions. As the recurrences were always characterised by an overt inflammatory phenotype (characterised by fever, increased C-reactive protein, and pericardial effusion), we administered off-label tocilizumab (an IL-6 receptor antagonist) as a last treatment option. The patient gained rapid benefit and was able to discontinue steroid therapy during the 6-month follow-up, achieving complete recovery from pericarditis. Discussion Interleukin-6 is a key cytokine in the pathogenesis of pericarditis, acting synergistically with IL-1 to drive inflammation and acute phase responses. In our patient, blockade of IL-6 with tocilizumab led to the complete resolution of inflammation, suggesting a possible new therapeutic option for refractory cases. This result highlights the potential of IL-6 inhibition as an alternative strategy, when IL-1 blockers are contraindicated or ineffective.
  • Pubblicazione
    Breastfeeding after breast cancer in young BRCA carriers
    ( 2025)
    Blondeaux E.
    ;
    Delucchi V.
    ;
    Mariamidze E.
    ;
    Bernstein-Molho R.
    ;
    Frank S.
    ;
    Ferrari A.
    ;
    Linn S.
    ;
    Kim H. J.
    ;
    Agostinetto E.
    ;
    Paluch-Shimon S.
    ;
    Cortesi L.
    ;
    Di Meglio A.
    ;
    Balmana J.
    ;
    Yerushalmi R.
    ;
    Rodriguez-Wallberg K. A.
    ;
    Renaud T.
    ;
    Cui W.
    ;
    Moore H. C. F.
    ;
    Wong S. M.
    ;
    Pogoda K.
    ;
    Lustberg M.
    ;
    Phillips K. -A.
    ;
    Han S.
    ;
    Puglisi F.
    ;
    Vernieri C.
    ;
    Bajpai J.
    ;
    Sonnenblick A.
    ;
    Rousset-Jablonski C.
    ;
    De Marchis L.
    ;
    De Giorgi U.
    ;
    Bianchini G.
    ;
    Texeira L.
    ;
    Duhoux F. P.
    ;
    Villarreal-Garza C.
    ;
    Sini V.
    ;
    Fruscio R.
    ;
    Del Mastro L.
    ;
    Demeestere I.
    ;
    Azim H. A.
    ;
    Peccatori F. A.
    ;
    Partridge A. H.
    ;
    Lambertini M.
    Background We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS), and overall survival (OS) were compared between patients who breastfed after delivery and those who did not. Results Among 4732 patients included from 78 centers worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%). After a median follow-up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 36% in the no breastfeeding group (adjusted subdistribution hazard ratio [HR] = 1.08, 95% CI = 0.57 to 2.06). No difference in DFS (adjusted hazard ratio [aHR] = 0.83, 95% CI = 0.49 to 1.41) nor in OS (aHR = 1.32, 95% CI = 0.31 to 5.66) was observed. Conclusions Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety.